[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571518":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":29,"locations":35,"responsibleParty":89,"collaborators":92,"id":99,"slug":28,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":100,"sex":106,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":28,"studyType":112,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":37,"whyStopped":28,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"University of Kansas Medical Center","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Clenbuterol Cohort 1","EXPERIMENTAL","20 mcg taken orally twice daily",[13],"Drug: Clenbuterol",{"label":15,"type":10,"description":16,"interventionNames":17},"Clenbuterol Cohort 2","40 mcg taken orally twice daily",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Clenbuterol Cohort 3","60 mcg taken orally twice daily",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Clenbuterol","Beta-Agonist",[9,15,19],null,[30],{"name":31,"role":32,"phone":33,"phoneExt":28,"email":34},"Rebecca Clay","CONTACT","9139459936","rclay@kumc.edu",[36,55,72],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Kansas City","Kansas","66160","United States",{"type":43,"coordinates":44},"Point",[45,46],-94.62746,39.11417,{"lat":46,"lon":45},[49,52],{"name":50,"role":32,"phone":51,"phoneExt":28,"email":34},"Rebecca Clay, BS","913-945-9936",{"name":53,"role":54,"phone":28,"phoneExt":28,"email":28},"Jeffrey Statland","PRINCIPAL_INVESTIGATOR",{"facility":56,"status":37,"city":57,"state":58,"zip":59,"country":41,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"University of Rochester Medical Center","Rochester","New York","14642",{"type":43,"coordinates":61},[62,63],-77.61556,43.15478,{"lat":63,"lon":62},[66,70],{"name":67,"role":32,"phone":68,"phoneExt":28,"email":69},"Leann Lewis, MSGC","585-275-7680","Leann_Lewis@URMC.Rochester.edu",{"name":71,"role":54,"phone":28,"phoneExt":28,"email":28},"Brianna Brun",{"facility":73,"status":37,"city":74,"state":75,"zip":76,"country":41,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"University of Washington","Seattle","Washington","98104",{"type":43,"coordinates":78},[79,80],-122.33207,47.60621,{"lat":80,"lon":79},[83,87],{"name":84,"role":32,"phone":85,"phoneExt":28,"email":86},"Lilly Young","206-616-5957","eyoung8@uw.edu",{"name":88,"role":32,"phone":28,"phoneExt":28,"email":28},"Leo Wang",{"type":90,"investigatorFullName":53,"investigatorTitle":91,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"SPONSOR_INVESTIGATOR","Professor of Neurology",[93,94,97],{"name":73,"class":6},{"name":95,"class":96},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","NIH",{"name":98,"class":6},"University of Rochester","100571518",false,"NCT06721299","Clenbuterol to Target DUX4 in FSHD","Clenbuterol to Target DUX4 in FSHD (Target FSHD): Open Label Safety and Tolerability Study of 3 Doses of Clenbuterol","Target FSHD","Inclusion Criteria:\n\n* Genetically confirmed diagnosis of FSHD type 1 or 2, or have a clinical diagnosis of FSHD type 1 with a first degree relative with confirmed mutation\n* between 18 and 75 years of age\n* with a clinical severity score between 0 and 10\n* Able to walk 30ft without support of another person\n* Showing anti-gravity strength on at least one of the tibialis anterior muscles or having an MRI eligible muscle in the leg for needle biopsy\n* willing and able to provide informed consent\n* agree to follow the contraceptive requirement for duration of the study\n\nExclusion Criteria:\n\n* Pregnant or planning to become pregnant during the conduct of the study\n* have a poorly controlled medical condition\n* Were involved in a study of an experimental agent within 3 months of enrollment\n* Are taking beta-blockers or anabolic agent or potassium wasting diuretics\n* Are taking or are planning to take a GLP-1 Agonist during trial\n* have any condition or contraindication which would interfere with testing or preclude use of beta-agonist\n* Are taking blood thinners or medications which make a needle muscle biopsy contra-indicated\n* Has contraindication to lactose such as galactosmia, lactase deficiency and glucose-galactose malabsorption. For those who are lactose intolerant, the PI will determine acceptability based on tolerance reaction to lactose\n* Are taking any medications or therapies with a contraindication to Clenbuterol","ALL","18 Years","75 Years",{"count":110,"type":111},30,"ESTIMATED","INTERVENTIONAL",[114],"PHASE1","The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.",[117],"Muscular Dystrophy, Facioscapulohumeral",[119],"FSHD","2026-02-24",{"date":122,"type":123},"2026-02-25","ACTUAL",{"date":125,"type":123},"2025-06-25",{"date":127,"type":111},"2028-07",{"name":53,"class":6},3]